The life science and biotech PR distribution service

Vetter Contributes to Commercial Launches of Eight Customer Products in 2023

Vetter logo

Portfolio of early- and late-stage clinical services advances product development for injectables

  • Vetter successfully brought eight customer drugs to market after supporting them through the development phases
  • As an established leader in commercial fill and finish, Vetter has evolved as a trusted provider of drug product development services
  • New molecules candidates brought to Vetter in the clinic receive strategic counsel and experienced support to guide their path to market and beyond

RAVENSBURG, Germany, February 14, 2024 / Biotech Newswire / -- Vetter, a leading globally operating contract development and manufacturing organization (CDMO) announces the successful commercialization of eight customer drug products as of the completion of 2023. The products were supported by the comprehensive portfolio of the Vetter Development Service during their drug development phases. The drug products that reached the world market are used in oncology and to treat autoimmune and cardiovascular diseases, among others. Their nature and administration vary widely, ranging from emergency medications to long-term and life-enhancing therapies for patients. The drugs also vary in delivery methods, which include self-administration for at-home care and administration by healthcare professionals.

“Bringing a promising therapy through the clinical phase to market readiness and launch is a challenging journey that culminates years of development work. Our holistic development service offerings build on one another and become interlinked,” shared Dr. Claus Feussner, Senior Vice President Vetter Development Service. “This allows us to support our customer’s products throughout the entire development cycle to commercialization and beyond. Our individualized capabilities have allowed us to support more than 50 market launches over the past five years.”

Vetter has significantly expanded its clinical capabilities in recent years, both in terms of production capacity, analytical offerings, and personnel. The Vetter Development Service is one of the three pillars of the CDMO, complementing Vetter Commercial Manufacturing and Vetter Secondary Packaging and Assembly. The CDMO is currently supporting more than 200 projects in early and late clinical phases as well as life-cycle development. With two dedicated clinical manufacturing sites in Skokie, USA, and Rankweil, Austria, the pharmaceutical service provider supports clinical batch production for in-human trials in early development. Late-stage development, including process design, method transfer and handover to quality and production for commercial manufacturing and launch, takes place in Ravensburg, Germany.

pic1    pic2

© Vetter Pharma International GmbH: The experts of the Vetter Development Service support customer products through the clinic with passion, know-how and high-quality equipment.

For high resolution please click the images.

Find the Vetter press kit and more background information here.


About Vetter
Vetter is a leading Contract Development and Manufacturing Organization (CDMO) with headquarters in Ravensburg, Germany, and production facilities in Germany, Austria, and the US. As a global player, the pharmaceutical service provider is also present with its own sales locations in the Asia-Pacific markets of Japan, China, South Korea and Singapore. Around the world, small and large renowned pharma and biotech companies rely on the decades of experience, high quality, modern technologies, reliability, and commitment of more than 6,300 employees. In close partnership with its customers, the Vetter team supplies patients all over the world with medicines, many of which are vital. The CDMO provides support from drug product development through clinical and commercial filling to a wide range of assembly and packaging services for vials, syringes, and cartridges. With innovative solutions, Vetter develops prefilled drug-delivery systems together with its customers to continuously improve patient safety, comfort, and compliance. The company is an industry pioneer in sustainability and a socially and ethically responsible corporate citizen. The CDMO is a member of the UN Global Compact and Science Based Target initiative (SBTi) and received platinum status in the renowned EcoVadis ranking. Multiple awards such as the CDMO Leadership Awards, Frost & Sullivan Customer Value Leadership award or the recognition as Best Managed Company emphasize Vetter’s commitment to sustainable business. Founded in Ravensburg in 1950, the company remains family-owned to this day. Learn more at www.vetter-pharma.com.



Vetter Pharma International GmbH
Markus Kirchner
Corporate Spokesperson / Media Relations
Eywiesenstrasse 5
88212 Ravensburg
+49 (0)751-3700-3729
This email address is being protected from spambots. You need JavaScript enabled to view it.

Keywords: Drug Development; Research; Pharmaceutical Services; Biotechnology; Pharmaceutical Preparations; Laboratories; Drug Packaging; Product Packaging; Drug Delivery Systems; Syringes; Outsourced Services; Commerce; Biological Products; Germany; Vetter; Commercial launches; Customer products; Clinical services; Product development; Injectables; Fill and finish; Drug product development services; Molecules candidates; Clinic; Strategic counsel; Contract development and manufacturing organization (CDMO); Emergency medications; Life-enhancing therapies; Delivery methods; Self-administration; Healthcare professionals; Therapy; Development cycle; Commercialization; Dr. Claus Feussner; Production capacity; Analytical offerings; Vetter Development Service; Vetter Commercial Manufacturing; Vetter Secondary Packaging and Assembly; Early clinical phases; Late clinical phases; Life-cycle development; Clinical manufacturing sites

Published by Biotech Newswire

Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.